Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RVMD Revolution Medicines, Inc.

盘前交易 11-05 04:55:39 EST

199.70

+5.47

+2.82%

盘前212.50

+12.80+6.41%

04:47 EST

最高201.79	最低192.34	成交量255.03万
今开198.50	昨收194.23	日振幅4.87%
总市值428.03亿	流通市值369.45亿	总股本2.14亿
成交额5.08亿	换手率1.38%	流通股本1.85亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RVMD","market":"US","secType":"STK","nameCN":"Revolution Medicines, Inc.","latestPrice":199.7,"timestamp":1793826000000,"preClose":194.23,"halted":0,"volume":2550322,"hourTrading":{"tag":"盘前","latestPrice":212.5,"preClose":199.7,"latestTime":"04:47 EST","volume":696,"amount":146527.34184,"timestamp":1793872031820,"change":12.8,"changeRate":0.064096,"amplitude":0.032349},"delay":0,"changeRate":0.028162487772228798,"floatShares":185000000,"shares":214336418,"eps":-8.921187,"marketStatus":"盘前交易","change":5.47,"latestTime":"11-05 04:55:39 EST","open":198.5,"high":201.79,"low":192.34,"amount":507881859.93561995,"amplitude":0.048654,"askPrice":214.5,"askSize":117,"bidPrice":210,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-8.921187,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793889000000},"marketStatusCode":1,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":199.7,"preHourTrading":{"tag":"盘前","latestPrice":212.5,"preClose":199.7,"latestTime":"04:47 EST","volume":696,"amount":146527.34184,"timestamp":1793872031820,"change":12.8,"changeRate":0.064096,"amplitude":0.032349},"postHourTrading":{"tag":"盘后","latestPrice":212,"preClose":199.7,"latestTime":"19:59 EST","volume":262666,"amount":56946834.2164,"timestamp":1793840360501,"change":12.3,"changeRate":0.061592,"amplitude":0.141713},"volumeRatio":2.082702279985769,"impliedVol":0.6446,"impliedVolPercentile":0.756},"requestUrl":"/m/hq/s/RVMD","defaultTab":"news","newsList":[{"id":"1145005723","title":"异动解读｜Revolution Medicines夜盘上涨5.25%，季报亏损好于预期且收入显著超市场预估","url":"https://stock-news.laohu8.com/highlight/detail?id=1145005723","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145005723?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:28","pubTimestamp":1793842105,"startTime":"0","endTime":"0","summary":"11月5日，Revolution Medicines夜盘上涨5.25%，报210.19美元/股，成交额1.34万美元。消息面上，公司披露季度业绩后获得资金关注：当季每股亏损为1.90美元，好于市场预期的2.42美元；收入为1.97559亿美元，显著高于此前市场预估的2349.5万美元。同时，市场继续关注RASONQUE商业化放量前景。此前机构曾指出，该药8月获批后早期处方转换、支付准入和医生接受度表现积极，且公司已推进多项III期联合治疗研究，强化了中长期收入增长预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Revolution Medicines夜盘上涨，季报收入大超预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141171911","title":"异动解读｜Revolution Medicines, Inc.盘后上涨8.47%，季度收入预期与新药放量前景受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=1141171911","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141171911?lang=zh_cn&edition=full","pubTime":"2026-11-05 05:03","pubTimestamp":1793826195,"startTime":"0","endTime":"0","summary":"11月5日，Revolution Medicines, Inc.盘后上涨8.47%，报212.35美元/股，成交额297.26万美元。消息面上，公司于11月4日盘后披露季度业绩，市场此前一致预期本季度总收入为2548.17万美元，同比增长15.11%；机构同时持续看好RASONQUE上市后放量前景，认为其有望成为后续收入增长核心驱动。此前多家机构提到，RASONQUE于8月获批治疗转移性胰腺癌后，早期处方转换、支付准入和医生接受度表现积极；与此同时，公司10月启动多项III期联合治疗研究，也强化了市场对其中长期产品线扩张的预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Revolution Medicines盘后上涨，新药放量前景受关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136723294","title":"财报前瞻 | Revolution Medicines, Inc.本季度营收预计增15.11%，机构多数看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1136723294","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136723294?lang=zh_cn&edition=full","pubTime":"2026-10-28 08:50","pubTimestamp":1793148638,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc.将于2026年11月4日盘后发布财报，市场聚焦RASONQUE商业化放量与费用曲线对利润路径的影响。一致预期显示，本季度总收入预计为2,548.17万美元，同比增长15.11%；调整后每股收益预计为-2.41，同比变动-69.84%；息税前利润预计为-5.24亿，同比变动-85.59%；毛利率与净利率暂无一致预期披露。公司当前主营业务以合作收入为主，上季度“合作”收入约1,158.00万美元，占比100.00%，对应口径的同比数据未披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | Revolution Medicines, Inc.本季度营收预计增15.11%，机构多数看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116756284","title":"异动解读｜Revolution Medicines, Inc.盘中上涨5.43%，启动肺癌三期联合疗法试验患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1116756284","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116756284?lang=zh_cn&edition=full","pubTime":"2026-10-20 22:04","pubTimestamp":1792505088,"startTime":"0","endTime":"0","summary":"10月20日，Revolution Medicines, Inc.盘中上涨5.43%，报192.04美元/股，成交额6405.14万美元。消息面上，公司宣布已在三期RASolve 308试验中开始为患者给药，评估zoldonrasib联合帕博利珠单抗及化疗，作为转移性RAS G12D非鳞状非小细胞肺癌一线治疗方案。此前公司还于10月初启动胰腺癌一线治疗三期RASolute 309试验；叠加Rasonque自8月获批后上市初期反馈积极，多家机构近期维持买入或跑赢大市评级，强化了市场对其商业化与管线推进的预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Revolution Medicines盘中上涨，启动肺癌三期联合疗法","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152324865","title":"异动解读｜Revolution Medicines盘中下跌5.02%，市场消化Rasonque早期放量预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1152324865","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152324865?lang=zh_cn&edition=full","pubTime":"2026-10-16 23:25","pubTimestamp":1792164319,"startTime":"0","endTime":"0","summary":"10月16日，Revolution Medicines盘中下跌5.02%，报179.76美元/股，成交额1.11亿美元。消息面上，最新催化来自机构对Rasonque上市初期表现的更新。RBC表示，该药自8月获批用于胰腺癌后，市场反馈积极，早期准入环节虽仍受支付方对接和处方材料推动影响，但已有早期用药项目患者转入商业化用药，并预计强劲上市表现可带来第三季度约3600万美元收入。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines盘中下行，市场消化Rasonque放量预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157993410","title":"异动解读｜Revolution Medicines盘中下跌5.23%，生物科技板块普跌拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1157993410","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157993410?lang=zh_cn&edition=full","pubTime":"2026-10-06 22:13","pubTimestamp":1791295997,"startTime":"0","endTime":"0","summary":"10月6日，Revolution Medicines盘中下跌5.23%，报197.13美元/股，成交额4144.94万美元。该公司所在的生物科技行业中，整体表现疲软，个股中，Vaxcyte下跌11.45%，Moderna下跌6.06%，Natera下跌5.54%，Twist Bioscience下跌4.92%，安进下跌1.08%。Revolution Medicines是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法以抑制RAS成瘾癌症的前沿靶点，拥有先进的基于结构的药物发现能力及针对RAS通路关键信号节点的深层研发管线。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169773730","title":"异动解读｜Revolution Medicines盘中上涨5.06%，多家投行上调目标价叠加FDA突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1169773730","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169773730?lang=zh_cn&edition=full","pubTime":"2026-09-25 23:46","pubTimestamp":1790351218,"startTime":"0","endTime":"0","summary":"9月25日，Revolution Medicines盘中上涨5.06%，报210.03美元/股，成交额1.91亿美元。消息面上，近期多重利好持续发酵。9月15日，公司核心产品Rasonque联合化疗获FDA突破性疗法认定，用于一线转移性胰腺癌治疗，进一步拓宽商业化前景。此前Rasonque已于8月底获FDA批准上市，30天疗程定价39,800美元。RBC预计Rasonque将实现快速放量，估算全年美国销售额约2.49亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Revolution Medicines获突破性疗法，投行集体上调目标价","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144894003","title":"异动解读｜Revolution Medicines盘中上涨5.09%，多家投行上调目标价叠加FDA突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1144894003","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144894003?lang=zh_cn&edition=full","pubTime":"2026-09-25 03:37","pubTimestamp":1790278646,"startTime":"0","endTime":"0","summary":"9月25日，Revolution Medicines盘中上涨5.09%，报200.44美元/股，成交额5.38亿美元。消息面上，近期多重利好持续发酵。9月15日，公司核心产品Rasonque联合化疗获FDA突破性疗法认定，用于一线转移性胰腺癌治疗，进一步拓宽商业化前景。Rasonque于8月底获FDA批准上市，30天疗程定价39,800美元，RBC预计该药将实现快速放量，预估全年美国销售额达2.49亿美元。Revolution Medicines成立于2014年，是一家精准肿瘤学公司，专注于开发靶向RAS成瘾癌症的创新疗法，拥有深厚的化学生物学和药物发现能力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"获FDA突破性疗法认定，股价强势上涨","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193246198","title":"异动解读｜Revolution Medicines盘中下跌5.1%，报194.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193246198","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193246198?lang=zh_cn&edition=full","pubTime":"2026-09-17 03:19","pubTimestamp":1789586364,"startTime":"0","endTime":"0","summary":"9月17日，Revolution Medicines盘中下跌5.1%，报194.42美元/股，成交额3.34亿美元。Revolution Medicines所在的生物科技行业中，个股表现分化。行业个股中，Moderna跌0.78%，艾伯维跌0.49%，安进跌0.02%，吉利德科学涨0.66%，Natera跌1.76%。Revolution Medicines是一家临床阶段精准肿瘤学公司，专注于开发靶向RAS成瘾癌症的疗法。其核心产品Rasonque已获FDA批准用于转移性胰腺癌治疗，并于近日获得突破性疗法认定用于一线联合化疗方案。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165924054","title":"Revolution Medicines宣布Rasonque™（Daraxonrasib）联合化疗获美国FDA突破性疗法认定，用于一线转移性胰腺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1165924054","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165924054?lang=zh_cn&edition=full","pubTime":"2026-09-15 04:06","pubTimestamp":1789416374,"startTime":"0","endTime":"0","summary":"Revolution Medicines, Inc.今日宣布，其研发的创新药物Rasonque与化疗药物联用，已获得美国食品药品监督管理局授予的突破性疗法认定。这一认定针对的适应症为一线治疗转移性胰腺癌。此项突破性疗法认定标志着该联合治疗方案在临床试验中展现出显著的治疗潜力，有望为预后极差的转移性胰腺癌患者带来新的治疗选择。这一进展不仅为Revolution Medicines的研发管线注入了强劲动力，也让医学界对攻克胰腺癌这一顽固性疾病增添了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","IE00B2B36J28.USD","LU0109394709.USD","CANC","IE00BFTCPJ56.SGD","RVMD","LU0889565916.HKD","IE0009354923.USD","IE00B4R5TH58.HKD","IE0009355771.USD","IDNA","IE0002141913.USD","BK4139","LU0320765992.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186962882","title":"Revolution Medicines获摩根士丹利首次覆盖，给予“增持”评级，目标价255美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186962882","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186962882?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:10","pubTimestamp":1789035009,"startTime":"0","endTime":"0","summary":"摩根士丹利近日宣布首次覆盖生物制药公司Revolution Medicines, Inc.，并给予其“增持”评级。该机构将目标股价设定为每股255美元。这一举措标志着华尔街主要投行对这家专注于研发创新疗法的企业前景持乐观态度。值得注意的是，摩根士丹利的这一评级和价格目标，为投资者提供了新的参考坐标。此前，市场对Revolution Medicines的关注度持续攀升，尤其在肿瘤治疗领域，其管线布局备受瞩目。此次覆盖报告的出炉，或将在短期内影响该股的市场情绪与交易动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","CANC","IE0009355771.USD","LU0320765992.SGD","LU0889565916.HKD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4139","IE0009354923.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IDNA","IE0002141913.USD","PTH","IE00BJT1NW94.SGD","RVMD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666554138","title":"Stifel上调Revolution Medicines目标价至230美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666554138","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666554138?lang=zh_cn&edition=full","pubTime":"2026-09-10 11:17","pubTimestamp":1789010271,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IDNA","UDN","LU0109394709.USD","IE0009354923.USD","BBH","UUP","IE0009355771.USD","BK4139","PTH","RVMD","IE00B4R5TH58.HKD","IE0002141913.USD","IE00BJT1NW94.SGD","CANC","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0320765992.SGD","LU0889565916.HKD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106079427","title":"异动解读｜Revolution Medicines盘中下跌5.02%，新药获批利好兑现后遭获利了结","url":"https://stock-news.laohu8.com/highlight/detail?id=1106079427","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106079427?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:31","pubTimestamp":1787927476,"startTime":"0","endTime":"0","summary":"8月28日，Revolution Medicines盘中下跌5.02%，报210.055美元/股，成交额1.04亿美元。消息面上，FDA于8月26日正式批准公司旗下首款RAS靶向口服药Rasonque上市，用于治疗转移性胰腺癌，将患者中位生存期从6.7个月延长至13.2个月。该药年费超47.5万美元，30天疗程批发价39,800美元。然而，公司股价年内累计涨幅已超166%，市场此前已充分预期获批，属典型\"利好兑现\"式回调。此外，当日生物科技板块整体承压，Moderna跌5.72%、BioNTech跌8.15%，行业情绪偏弱亦加剧跌势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"新药获批利好兑现，Revolution Medicines回落","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662061828","title":"美国FDA批准胰腺癌突破性药物 独立药企Revolution Medicines迎里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662061828","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662061828?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:15","pubTimestamp":1787912149,"startTime":"0","endTime":"0","summary":"Revolution Medicines历时近十年持续攻关，在500人规模临床试验中获得积极数据，最终获得监管批准。为完成交易，戈德史密斯与Warp Drive最大股东赛诺菲协商，将后者持有的Warp Drive多数股权置换为Revolution Medicines的部分股权，最终达成协议。在正式获批前，美国食品药品管理局已通过同情用药项目允许Revolution Medicines提前约四个月向患者分发药物，截至获批时已有超过2000名患者纳入该项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-28/doc-inipwhrt5845666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["IE0002141913.USD","LABU","IE00BFTCPJ56.SGD","BK4585","IE0009354923.USD","IE00BJT1NW94.SGD","LU0320765992.SGD","IE00B4R5TH58.HKD","CANC","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","RVMD","BBH","IDNA","LU0889565916.HKD","PTH","LU0109394709.USD","IE0009355771.USD","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662722025","title":"杰富瑞：将Revolution Medicines目标价从242美元上调至270美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662722025","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662722025?lang=zh_cn&edition=full","pubTime":"2026-08-27 11:50","pubTimestamp":1787802605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","IE0009355771.USD","RVMD","IE00BJT1NW94.SGD","LU0109394709.USD","BBH","IE00B2B36J28.USD","PTH","IE00BJJMRZ35.SGD","IE0009354923.USD","LU0889565916.HKD","LU0320765992.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","CANC","UUP","UDN","IE0002141913.USD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662741140","title":"胰腺癌治疗迎历史性突破！FDA批准RevMed靶向新药，预计2032年销售超90亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662741140","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662741140?lang=zh_cn&edition=full","pubTime":"2026-08-27 03:59","pubTimestamp":1787774360,"startTime":"0","endTime":"0","summary":"$Revolution Medicines$旗下胰腺癌新药daraxonrasib获得$美国食品$药品监督管理局批准上市，成为首款针对该疾病关键分子致病机制的靶向药物，标志着胰腺癌治疗领域多年来最重要的突破之一。该药以商品名Rasonque上市，年标价超47.5万美元。消息公布后，RevMed股价上涨，截至发稿盘中上涨2.5%，今年以来累计涨幅已超过一倍，公司市值突破450亿美元。华尔街分析师预测，该药2032年销售额有望超过90亿美元。","market":"us","thumbnail":"https://static.tigerbbs.com/cf00d3e001bd81b11eb9b57bd44b96ab","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/cf00d3e001bd81b11eb9b57bd44b96ab"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3780372","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"胰腺癌治疗迎历史性突破！FDA批准RevMed靶向新药，预计2032年销售超90亿美元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","RVMD","BK4588"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1164882019","title":"Revolution Medicines旗下Rasonque美国正式上市，30天疗程批发采购价39,800美元——电话会议披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1164882019","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164882019?lang=zh_cn&edition=full","pubTime":"2026-08-27 01:57","pubTimestamp":1787767031,"startTime":"0","endTime":"0","summary":"Revolution Medicines公司日前宣布，其研发的Rasonque药物现已在美国市场正式商业化供应。这款产品的批发采购成本定为39,800美元，对应30天的用药剂量。值得注意的是，此次上市定价反映了Rasonque在精准肿瘤治疗领域的差异化价值主张。从商业角度看，这一价格策略也释放出Revolution Medicines对其产品竞争力的强烈信心。分析人士指出，随着Rasonque正式进入流通渠道，相关供应链与市场准入工作已全面启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","IE0009354923.USD","BBH","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IDNA","LU0320765992.SGD","IE0002141913.USD","RVMD","PTH","IE00B4R5TH58.HKD","BK4139","IE0009355771.USD","LU0109394709.USD","IE00B2B36J28.USD","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156385670","title":"美国FDA批准Revolution Medicines旗下Rasonque™（Daraxonrasib）上市，开创转移性胰腺癌广谱Ras靶向治疗先河","url":"https://stock-news.laohu8.com/highlight/detail?id=1156385670","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156385670?lang=zh_cn&edition=full","pubTime":"2026-08-27 01:00","pubTimestamp":1787763644,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局正式批准了Revolution Medicines研发的Rasonque——这标志着全球首款针对转移性胰腺癌的广谱Ras靶向药物成功问世。此举不仅为晚期胰腺癌患者带来了全新的治疗选项，更在肿瘤精准医疗领域树立起一座重要的里程碑。此次获批，无疑将深刻影响胰腺癌治疗的现有格局。对于广大深受胰腺癌困扰的患者群体而言，Rasonque的上市，无疑为他们与病魔的抗争增添了一件有力武器。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","PTH","BK4139","IDNA","IE00B4R5TH58.HKD","CANC","BBH","LU0109394709.USD","IE00BJJMRZ35.SGD","IE0009354923.USD","IE00BJT1NW94.SGD","LU0320765992.SGD","IE0009355771.USD","RVMD","LU0889565916.HKD","IE0002141913.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662482997","title":"Revolution Medicines的胰腺癌药物 Daraxonrasib已获得美国监管机构的批准，这是首款针对胰腺","url":"https://stock-news.laohu8.com/highlight/detail?id=2662482997","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662482997?lang=zh_cn&edition=full","pubTime":"2026-08-26 23:14","pubTimestamp":1787757271,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","CANC","BK4139","LU0889565916.HKD","IE00B2B36J28.USD","RVMD","BBH","IE0009355771.USD","IE0002141913.USD","IE0009354923.USD","PTH","LU0320765992.SGD","IDNA","IE00BJJMRZ35.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114413981","title":"异动解读｜Revolution Medicines盘中下跌5.34%，报200.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1114413981","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114413981?lang=zh_cn&edition=full","pubTime":"2026-08-26 22:45","pubTimestamp":1787755511,"startTime":"0","endTime":"0","summary":"8月26日，Revolution Medicines盘中下跌5.34%，报200.13美元/股，成交额8347.87万美元。Revolution Medicines所在的生物科技行业中，个股中，Moderna下跌5.87%，安进下跌0.36%，艾伯维公司下跌1.38%，吉利德科学持平，Natera上涨1.13%。Revolution Medicines是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法以抑制RAS成瘾癌症的前沿靶点，拥有先进的基于结构的药物发现能力。公司过去52周累计涨幅超470%，近期股价处于历史高位区间。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revmed.com;ir.revmed.com","stockEarnings":[{"period":"1week","weight":0.0582},{"period":"1month","weight":-0.0384},{"period":"3month","weight":0.0096},{"period":"6month","weight":0.4082},{"period":"1year","weight":2.4096},{"period":"ytd","weight":1.5072}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":-0.0104},{"period":"3month","weight":-0.0023},{"period":"6month","weight":0.0396},{"period":"1year","weight":0.1356},{"period":"ytd","weight":0.1245}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Revolution Medicines, Inc.成立于2014年10月，是特拉华州的一家公司。该公司是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法，以抑制RAS成瘾癌症的前沿靶点。该公司拥有先进的基于结构的药物发现能力，其基础是深厚的化学生物学和癌症药理学知识以及创新的专有技术，能够创造适合非常规结合位点的小分子。该公司对癌症的遗传驱动因素和适应性耐药机制的了解，加上强大的药物发现和药物化学能力，指导建立了一个针对RAS通路和相关通路中的关键信号节点的深层管道。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.034782},{"month":2,"riseRate":0.666667,"avgChangeRate":0.00452},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.031822},{"month":4,"riseRate":0.714286,"avgChangeRate":0.114077},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.015463},{"month":6,"riseRate":0.857143,"avgChangeRate":0.063598},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.000417},{"month":8,"riseRate":0.714286,"avgChangeRate":0.065126},{"month":9,"riseRate":0.428571,"avgChangeRate":0.032485},{"month":10,"riseRate":0.571429,"avgChangeRate":0.00739},{"month":11,"riseRate":0.857143,"avgChangeRate":0.167771},{"month":12,"riseRate":0.5,"avgChangeRate":-0.027192}],"exchange":"NASDAQ","name":"Revolution Medicines, Inc.","nameEN":"Revolution Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Revolution Medicines, Inc.(RVMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Revolution Medicines, Inc.,RVMD,Revolution Medicines, Inc.股票,Revolution Medicines, Inc.股票老虎,Revolution Medicines, Inc.股票老虎国际,Revolution Medicines, Inc.行情,Revolution Medicines, Inc.股票行情,Revolution Medicines, Inc.股价,Revolution Medicines, Inc.股市,Revolution Medicines, Inc.股票价格,Revolution Medicines, Inc.股票交易,Revolution Medicines, Inc.股票购买,Revolution Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Revolution Medicines, Inc.(RVMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}